Compare · IGMS vs JNJ
IGMS vs JNJ
Side-by-side comparison of IGM Biosciences Inc. (IGMS) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IGMS and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $542.44B, about 968.1x IGMS ($560.3M).
- Over the past year, IGMS is up 0.0% and JNJ is up 45.1% - JNJ leads by 45.1 points.
- JNJ has hit the wire 27 times in the past 4 weeks while IGMS has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 24 for IGMS).
- Company
- IGM Biosciences Inc.
- Johnson & Johnson
- Price
- $1.27-1.92%
- $225.28-0.96%
- Market cap
- $560.3M
- $542.44B
- 1M return
- -5.90%
- -5.87%
- 1Y return
- +0.00%
- +45.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 27
- Recent ratings
- 24
- 25
IGM Biosciences Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of multiple diseases. Its lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). The company is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers and NHL; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. It has a strategic research and license agreement with AbCellera to discover and develop IgM antibodies; and license agreement with AvantGen Inc. for various antibodies against the SARS-CoV-2 virus. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest IGMS
- SEC Form 15-12G filed by IGM Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.
- SEC Form 4 filed by Former 10% owner and director Baker Bros. Advisors Lp
- Amendment: SEC Form SCHEDULE 13D/A filed by IGM Biosciences Inc.
- Director Redmile Group, Llc returned 2,964,843 shares to the company (SEC Form 4)
- SEC Form EFFECT filed by IGM Biosciences Inc.
- SEC Form EFFECT filed by IGM Biosciences Inc.
- SEC Form EFFECT filed by IGM Biosciences Inc.
- SEC Form EFFECT filed by IGM Biosciences Inc.
- SEC Form EFFECT filed by IGM Biosciences Inc.
Latest JNJ
- Johnson & Johnson filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Woods Eugene A.
- SEC Form 4 filed by Director West Nadja
- SEC Form 4 filed by Director Weinberger Mark A
- SEC Form 4 filed by Director Pinto Daniel E
- SEC Form 4 filed by Director Morikis John G
- SEC Form 4 filed by Director Mcclellan Mark B.
- SEC Form 4 filed by Director Joly Hubert
- SEC Form 4 filed by Director Johnson Paula A
- SEC Form 4 filed by Director Hewson Marillyn A